FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211748045> ?p ?o ?g. }

• W3211748045 endingPage "3693" @default.
• W3211748045 startingPage "3693" @default.
• W3211748045 abstract "Abstract Background: DDX41 gene is located on chromosome 5q35 and is believed to be a tumor suppressor gene involved in splicing of mRNA. Mutated DDX41 have been identified as germline mutation (m) in families with cases of myeloid neoplasm and have shown to cause acquisition of other somatic mutations resulting in MDS/AML. At the same time, somatic pathogenic DDX41 mutations are known to occur. Variant of unknown significance (VUS) is an intermediate tier between benign and pathogenic (path) mutations (hence uncertain) and can be re-classified based on their clinical impact. In this report we analyzed the clinical impact and relevance of DDX41VUS in patients (pts) being evaluated for myeloid disorders. Methods: We reviewed 4,524 consecutive pts who underwent NGS (MC OncoHeme 42 genes panel) testing between 2018 and 2021 performed on cases of suspected or known myeloid disorders. We identified 58 (1%) consecutive pts with DDX41VUS, among them one pt had proven concurrent DDX41 germline VUS and 7 pts with DDX41VUS had concurrent DDX41path mutation. We analyze clinical characteristics of pts with DDX41VUS and compared it with cohort of 32 DDX41path mutated pts. Results: Baseline characteristics are summarized in Table 1, and Figure 1 illustrates DDX41VUS per case with variant allele frequency (VAF) and observed concurrent mutations. The median VAF for DDX41 VUS was 48 % (range, 14-91%). Co-mutations were found in 14 (28%) pts with VUS, and the reminder (n=44, 72 %) had isolated DDX41VUS. Among them AML (16 [32%]), MDS (14 [28%]), cytopenia (14 [28%]) MPN (3 [6%]), CNL (1 [2%]) and aplastic anemia (1 [2%]) were the commonly occurring myeloid disorder (Table 1, Figure 1). Eleven of 14 pts with isolated cytopenia had isolated DDX41VUS. Conversely, among 15 evaluable pts with isolated DDX41VUS, 13 (87%) pts had normal cytogenetics and 40% of pts had family history of solid or hematological malignancies. We observed a significant difference in hematologic diagnoses: DDX41VUS patients were significantly less often diagnosed with MDS or CCUS, and more often associated with cytopenias NOS. Recurrent, non-random DDX41VUS sequences were observed; most frequent occurring amino acid change among the 58 pts were Gly173Arg (n=6), Met155lle (n=5), Pro258Leu (n=3) Arg479Gln (n=3), Val303Met (n=2), Lys331del (n=2), Arg479His (n=2) and Tyr33His (n=2) (Figure 1). 5 of 6 pts with Gly173Arg had isolated DDX41VUS, and among them 4 were diagnosed with MDS suggesting this could be a clonal event, and possible driver mutation, notable in Figure 1. The median overall survival (OS) of pts with high risk MDS/AML harboring DDX41VUS was not reached (60% alive at 2 years). Between pts with DDX41path and DDX41VUS, proportion of pts with co-mutations (p &gt;0.99), cytogenetic abnormalities (p &gt;0.99), family history of malignancies (p 0.52), time to treatment (p &gt;0.99), MDS progression to AML (p 0.36) and OS (among high risk MDS/AML pts) (p 0.55) was not significantly different, suggesting that phenotypic features of DDX41VUS are similar to DDX41path , and that both carry a similar, more indolent prognosis (Table 1). Conclusion: Our reports demonstrated that DDX41VUS occurs in 1% of patients with myeloid disorders and shares distinct diagnostic features but comparable prognostic features vs. DDX41path, including family history of hematological malignancies. It is possible that many of the cases with 'cytopenias' and DDX41VUS would meet criteria for CCUS if the variant was isolated classified as pathogenic, confirming the importance of extending our understanding of DDX41 variants. Further analysis to characterize the biological impact of DDX41VUS is underway. Figure 1 Figure 1. Disclosures Badar: Pfizer Hematology-Oncology: Membership on an entity's Board of Directors or advisory committees. Al-Kali: Novartis: Research Funding; Astex: Other: Research support to institution. Patnaik: Kura Oncology: Research Funding; Stemline Therapeutics: Membership on an entity's Board of Directors or advisory committees; Stemline Therapeutics: Membership on an entity's Board of Directors or advisory committees. Litzow: Astellas: Research Funding; Omeros: Other: Advisory Board; Jazz: Other: Advisory Board; Pluristem: Research Funding; Amgen: Research Funding; Biosight: Other: Data monitoring committee; Actinium: Research Funding; AbbVie: Research Funding. Foran: boehringer ingelheim: Research Funding; abbvie: Research Funding; takeda: Research Funding; trillium: Research Funding; revolution medicine: Honoraria; bms: Honoraria; servier: Honoraria; novartis: Honoraria; pfizer: Honoraria; aptose: Research Funding; taiho: Honoraria; certara: Honoraria; sanofi aventis: Honoraria; syros: Honoraria; actinium: Research Funding; gamida: Honoraria; OncLive: Honoraria; kura: Research Funding; h3bioscience: Research Funding; aprea: Research Funding; sellas: Research Funding; stemline: Research Funding." @default.
• W3211748045 created "2021-11-22" @default.
• W3211748045 creator A5005419037 @default.
• W3211748045 creator A5008422091 @default.
• W3211748045 creator A5013579871 @default.
• W3211748045 creator A5017327825 @default.
• W3211748045 creator A5035051206 @default.
• W3211748045 creator A5064856519 @default.
• W3211748045 creator A5072463255 @default.
• W3211748045 creator A5073183082 @default.
• W3211748045 creator A5079157559 @default.
• W3211748045 creator A5079731167 @default.
• W3211748045 creator A5082989235 @default.
• W3211748045 creator A5085360755 @default.
• W3211748045 date "2021-11-05" @default.
• W3211748045 modified "2023-10-16" @default.
• W3211748045 title "<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i>: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort" @default.
• W3211748045 doi "https://doi.org/10.1182/blood-2021-145115" @default.
• W3211748045 hasPublicationYear "2021" @default.
• W3211748045 type Work @default.
• W3211748045 sameAs 3211748045 @default.
• W3211748045 citedByCount "2" @default.
• W3211748045 countsByYear W32117480452022 @default.
• W3211748045 countsByYear W32117480452023 @default.
• W3211748045 crossrefType "journal-article" @default.
• W3211748045 hasAuthorship W3211748045A5005419037 @default.
• W3211748045 hasAuthorship W3211748045A5008422091 @default.
• W3211748045 hasAuthorship W3211748045A5013579871 @default.
• W3211748045 hasAuthorship W3211748045A5017327825 @default.
• W3211748045 hasAuthorship W3211748045A5035051206 @default.
• W3211748045 hasAuthorship W3211748045A5064856519 @default.
• W3211748045 hasAuthorship W3211748045A5072463255 @default.
• W3211748045 hasAuthorship W3211748045A5073183082 @default.
• W3211748045 hasAuthorship W3211748045A5079157559 @default.
• W3211748045 hasAuthorship W3211748045A5079731167 @default.
• W3211748045 hasAuthorship W3211748045A5082989235 @default.
• W3211748045 hasAuthorship W3211748045A5085360755 @default.
• W3211748045 hasConcept C104317684 @default.
• W3211748045 hasConcept C109825262 @default.
• W3211748045 hasConcept C126322002 @default.
• W3211748045 hasConcept C13514818 @default.
• W3211748045 hasConcept C143998085 @default.
• W3211748045 hasConcept C2779282312 @default.
• W3211748045 hasConcept C2780007613 @default.
• W3211748045 hasConcept C2780817109 @default.
• W3211748045 hasConcept C501734568 @default.
• W3211748045 hasConcept C502942594 @default.
• W3211748045 hasConcept C54355233 @default.
• W3211748045 hasConcept C63363279 @default.
• W3211748045 hasConcept C71924100 @default.
• W3211748045 hasConcept C86803240 @default.
• W3211748045 hasConceptScore W3211748045C104317684 @default.
• W3211748045 hasConceptScore W3211748045C109825262 @default.
• W3211748045 hasConceptScore W3211748045C126322002 @default.
• W3211748045 hasConceptScore W3211748045C13514818 @default.
• W3211748045 hasConceptScore W3211748045C143998085 @default.
• W3211748045 hasConceptScore W3211748045C2779282312 @default.
• W3211748045 hasConceptScore W3211748045C2780007613 @default.
• W3211748045 hasConceptScore W3211748045C2780817109 @default.
• W3211748045 hasConceptScore W3211748045C501734568 @default.
• W3211748045 hasConceptScore W3211748045C502942594 @default.
• W3211748045 hasConceptScore W3211748045C54355233 @default.
• W3211748045 hasConceptScore W3211748045C63363279 @default.
• W3211748045 hasConceptScore W3211748045C71924100 @default.
• W3211748045 hasConceptScore W3211748045C86803240 @default.
• W3211748045 hasIssue "Supplement 1" @default.
• W3211748045 hasLocation W32117480451 @default.
• W3211748045 hasOpenAccess W3211748045 @default.
• W3211748045 hasPrimaryLocation W32117480451 @default.
• W3211748045 hasRelatedWork W1489089338 @default.
• W3211748045 hasRelatedWork W150042935 @default.
• W3211748045 hasRelatedWork W1562693820 @default.
• W3211748045 hasRelatedWork W2010720786 @default.
• W3211748045 hasRelatedWork W2036729517 @default.
• W3211748045 hasRelatedWork W2098325466 @default.
• W3211748045 hasRelatedWork W2135108461 @default.
• W3211748045 hasRelatedWork W2201808132 @default.
• W3211748045 hasRelatedWork W2409614280 @default.
• W3211748045 hasRelatedWork W4232569475 @default.
• W3211748045 hasVolume "138" @default.
• W3211748045 isParatext "false" @default.
• W3211748045 isRetracted "false" @default.
• W3211748045 magId "3211748045" @default.
• W3211748045 workType "article" @default.